Tizanidine Hydrochloride

Phase 3Small molecule

EElan Pharmaceuticals

Tizanidine Hydrochloride is one of 37 small molecule programs targeting Migraine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineRecruiting

MigrainePhase 3

Recruiting

Competition

Competitive Landscape

105 competitors in Migraine

#DrugCompanyPhaseTrials

Zonegran

AAzurity Pharmaceuticals

Phase 3

3 2

Avicel

SSanthera Pharmaceuticals

Phase 3

2 3

Magnesium

SSpherium Biomed

Phase 3

3 4

Elismetrep

KKallyope Inc.

Phase 3

3 5

Flunarizine

AAspartes Pharmaceuticals, Inc.

Phase 3

9 6

Tizanidine Hydrochloride

EElan Pharmaceuticals

Phase 3

1 7

Bayer Aspirin

Bayer

Preclinical

2 8

Cymbalta

Jazz Pharmaceuticals

Preclinical

1 9

Adempas

Bayer

Preclinical

1 10

Cervidil

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spasticity1 trial

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

Completed·EElan Pharmaceuticals·Phase 3·NCT00047580·120 enrolled

Migraine1 trial

TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05484349·189 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tizanidine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tizanidine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tizanidine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Elan Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EElan Pharmaceuticals

Tizanidine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spasticity1 trial

Migraine1 trial

References

Drug Info

Quick Facts

Related News